Abstract
Objective: Serum markers measured early in pregnancy have been associated with the later diagnosis of gestational diabetes mellitus (GDM). This study aims to explore the performance of a panel of first-trimester biochemical markers for the prediction of GDM. Methods: A case-control study was performed that included 12 women who developed GDM and 60 controls matched for maternal and gestational age at blood collection. Levels of pregnancy-associated plasma protein A (PAPP-A), soluble endoglin, pregnancy protein 13, and adiponectin (Adipo) were measured on residual sera used in first-trimester screening for Down syndrome. Data were analyzed by nonparametric methods. A receiver operating characteristic curve was used to calculate the detection rate (DR) obtained with a panel of significant predictors for GDM. Results: Multiples of the median values for Adipo and PAPP-A were significantly reduced in GDM cases versus matched controls. Combination of Adipo and PAPP-A yielded a DR of 63.6% at a false-positive rate of 10%. Addition of body mass index (BMI) to this panel increased DR to 72.7%. Conclusion: This study suggests that first-trimester screening with Adipo, PAPP-A, and BMI may effectively identify women at high risk for the development of GDM.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop Conference on Gestational Diabetes Mellitus. The Organizing Committee. Diabetes Care. 1998;21(suppl 2):B161–B167.
Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 137: Gestational diabetes mellitus. Obstet Gynecol. 2013;122(2 pt 1):406–416.
American Diabetes Association. Gestational diabetes mellitus. Diabetes Care. 2002 Jan;25(suppl 1):s90–s93.
Donovan L, Hartling L, Muise M, Guthrie A, Vandermeer B, Dryden DM. Screening tests for gestational diabetes: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2013;159(2):115–122.
Solomon CG, Willett WC, Carey VJ, et al. A prospective study of pregravid determinants of gestational diabetes mellitus. JAMA. 1997;278(13):1078–1083.
Galtier F. Definition, epidemiology, risk factors. Diabetes Metab. 2010 36(6 pt 2):628–651.
Sacks DA, Hadden DR, Maresh M, et al; HAPO Study Cooperative Research Group. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study. Diabetes Care. 2012;35(3):526–528.
Athukorala C, Crowther CA, Willson K; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Women with gestational diabetes mellitus in the ACHOIS trial: risk factors for shoulder dystocia. Aust N Z J Obstet Gynecol. 2007;47(1):37–41.
Joffe GM, Esterlitz JR, Levine RG, et al. The relationship between abnormal glucose tolerance and hypotensive disorders of pregnancy in healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol. 1998;179(4):1032–1037.
van Hoorn J, Dekker G, Jeffries B. Gestational diabetes versus obesity as risk factors for pregnancy-induced hypertensive disorders and fetal macrosomia. Aust N Z J Obstet Gynecol. 2002;42(1):29–34.
Feig DS, Zinman B, Wang X, Hux JE. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. Can Med Assoc J. 2008;179(3):229–234.
Eleftheriades M, Papastefanou I, Lambrinoudaki I, et al. Elevated placental growth factor concentrations at 11-14 weeks of gestation to predict gestational diabetes mellitus. Metabolism. 2014;63(11):1419–1425.
Nanda S, Savvidou M, Syngelaki A, Akolekar R, Nicolaides KH. Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenat Diagn. 2011;31(2):135–141.
Syngelaki A, Kotecha R, Pastides A, et al. First-trimester biochemical markers of placentation in screening for gestational diabetes mellitus. Metabolism. 2015;64(11):1485–1489.
van Leeuwen, Opmeer BC, Zweers EJK, et al. Estimating the risk of gestational diabetes mellitus: a clinical prediction model based on patient characteristics and medical history. BJOG. 2010;117(1):69–75.
Williams MA, Qiu C, Muy-Rivera M, et al. Plasma adiponectin concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus. J Clin Endocrinol Metab. 2004;89(5):2306–2311
Lain KY, Daftary AR, Ness RB, Roberts JM. First trimester adi-pocytokine concentrations and risk of developing gestational diabetes later in pregnancy. Clin Endocrinol. 2008;69(3):407–411.
Georgiou HM, Lappas M, Georgiou GM, et al. Screening for biomarkers predictive of gestational diabetes mellitus. Acta Diabetol. 2008;45(3):157e65.
Spencer K, Cowans NJ. The association between gestational diabetes mellitus and first trimester aneuploidy screening markers. Ann Clin Biochem. 2013;50(pt 6): 603–610.
Lovati E, Beneventi F, Simonetta M, et al. Gestational diabetes mellitus: including serum pregnancy-associated plasma protein-A testing in the clinical management of primiparous women? A case-control study. Diabetes Res Clin Pract. 2013 Jun;100(3):340–347.
Unverdorben L, Hüttenbrenner R, Knabl J, Jeschke U, Hutter S. Galectin-13/PP-13 expression in term placentas of gestational diabetes mellitus pregnancies. Placenta. 2015;36(2):191–198.
Lappas M. Markers of endothelial cell dysfunction are increased in human omental adipose tissue from women with pre-existing maternal obesity and gestational diabetes. Metabolism. 2014;63(6):860–873.
Zorn TM, Zúñiga M, Madrid E, et al. Maternal diabetes affects cell proliferation in developing rat placenta. Histol Histopathol. 2011;26(8):1049–1056.
Benirschke K, Kaufmann P, Baergen RN. Pathology of the Human Placenta. 5th ed. New York: Springer; 2006.
Kirkegaard I, Uldbjerg N, Oxvig C. Biology of pregnancy-associated plasma protein-A in relation to prenatal diagnostics: an overview. Acta Obstet Gynecol Scand. 2010;89(9):1118–1125.
Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302(2):179–188.
Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.
Luoto R, Laitinen K, Nermes M, et al. Impact of maternal probiotic-supplemented dietary counselling on pregnancy outcome and prenatal and postnatal growth: a double-blind, placebo-controlled study. Br J Nutr. 2010;103(12):1792–1799.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Farina, A., Eklund, E., Bernabini, D. et al. A First-Trimester Biomarker Panel for Predicting the Development of Gestational Diabetes. Reprod. Sci. 24, 954–959 (2017). https://doi.org/10.1177/1933719116675057
Published:
Issue Date:
DOI: https://doi.org/10.1177/1933719116675057